ArticleJournal of translational medicine2026
A decoy virus strategy using plant-produced SARS-CoV-2 virus-like-particles to inhibit infection and lung injury.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rapid emergence of highly transmissible and immune-evasive SARS-CoV-2 variants, including Omicron lineage strains, has reduced the effectiveness of existing vaccines and antiviral therapies. Safe and rapidly deployable biologics capable of limiting viral entry and attenuating early inflammatory responses remains needed, particularly for high-risk exposure settings.
methodsWe evaluated engineered non-replicating SARS-CoV-2 virus-like particles (VLPs), which structurally mimic the native virus, for antiviral and immunomodulatory effects in human induced pluripotent stem cell (iPSC)-derived lung organoids and K18-hACE2 transgenic mice. Cytopathic effects, viral RNA levels, cytokine expression, and lung pathology were quantified, while biodistribution and acute safety were assessed by fluorescence imaging and inflammatory profiling.
resultsPre-exposure of lung organoids to VLPs attenuated SARS-CoV-2-induced cytopathic injury, reduced viral replication and IL-6 expression, and preserved epithelial integrity. Intranasal administration in K18-human angiotensin-converting enzyme 2 (ACE2) mice achieved uniform pulmonary distribution without acute inflammatory responses. A single pre-exposure prophylaxis dose of high-titer VLPs reduced viral burden and IL-6 levels, attenuated lung injury, and improved clinical parameters. Fluorescent VLPs co-localized with ACE2 and underwent cellular uptake in Calu-3 cells, supporting a competitive decoy mechanism, while preservation of ACE2 expression in vivo suggested reduced virus-induced ACE2 downregulation.
conclusionsSARS-CoV-2 VLPs function as safe, non-replicating biologics that limit viral entry and attenuate downstream inflammation under pre-exposure conditions. Their stability, scalability, and intranasal support further development as a pre-exposure prophylactic strategy, while additional studies are required to determine efficacy against contemporary variants and under post-exposure conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.